


CORRECTION

Open Access



Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

Shahram Attarian^{1*} , Peter Young², Thomas H. Brannagan³, David Adams⁴, Philip Van Damme^{5,6}, Florian P. Thomas^{7,8}, Carlos Casanovas^{9,10}, Jafar Kafaie⁸, Céline Tard¹¹, Maggie C. Walter¹², Yann Péréon¹³, David Walk¹⁴, Amro Stino¹⁵, Marianne de Visser¹⁶, Camiel Verhamme¹⁶, Anthony Amato¹⁷, Gregory Carter¹⁸, Laurent Magy¹⁹, Jeffrey M. Statland²⁰ and Kevin Felice²¹

Correction to: Orphanet Journal of Rare Diseases (2021) 16:433

<https://doi.org/10.1186/s13023-021-02040-8>

Following publication of the original article [1], we have been notified that we should add one more author to the authors' group:

Jafar Kafaie 8

8 Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA

The original article was updated.

The online version of the original article can be found at <https://doi.org/10.1186/s13023-021-02040-8>

*Correspondence:

Shahram Attarian

Shahram.ATTARIAN@ap-hm.fr

¹Reference Center for Neuromuscular Disorders and ALS, CHU La Timone, Marseille, France

²Department of Neurology, Medical Park Bad Feilnbach, Bad Feilnbach, Germany

³Columbia University Medical Center, The Neurological Institute, New York, USA

⁴French Reference Center for Rare Peripheral Neuropathies, Service de Neurologie Adulte, APHP, CHU Bicêtre, Le Kremlin Bicêtre, France

⁵Department of Neurology, University Hospitals Leuven, KU, Leuven, Belgium

⁶Center for Brain & Disease Research, VIB, Leuven, Belgium

⁷Department of Neurology, Hackensack University Medical Center, Hackensack, USA

⁸Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA

⁹Neuromuscular Unit, Neurology Department, Bellvitge University Hospital, Barcelona, Spain

¹⁰Neurometabolic Diseases Group, Bellvitge Research Institute (IDIBELL) and CIBERER, Barcelona, Spain

¹¹U1171, Centre de référence des maladies neuromusculaires Nord Est Ile de France, Hôpital Salengro CHU de Lille, Lille, France

¹²Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University of Munich, Munich, Germany

¹³Centre de Référence Maladies Neuromusculaires AOC, Filnemus, Euro-NMD, CHU Nantes, Hôtel-Dieu, Nantes, France

¹⁴Clinical Neuroscience Research Unit, University of Minnesota, Minneapolis, USA

¹⁵University of Michigan Health System, Ann Arbor, MI, USA

¹⁶Department of Neurology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands

¹⁷Department of Neurology, Brigham and Women's Hospital, Boston, USA

¹⁸St. Luke's Rehabilitation Institute, Physical Medicine and Rehabilitation, Spokane, USA

¹⁹CHU Dupuytren, Limoges, France

²⁰University of Kansas Medical Center, Kansas City, USA

²¹Department of Neuromuscular Medicine, Hospital for Special Care, New Britain, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Published online: 01 April 2024

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Attarian, et al. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–tooth type 1A. 2021;16:433. <https://doi.org/10.1186/s13023-021-02040-8>.